06826 HAOHAI BIOTEC
- 41.950
- -0.150-0.36%
HAOHAI BIOTEC News
On May 17, Haohai Biotechnology (06826.HK) spent 4.3037 million yuan to buy back 47,200 A shares
Gelonghui, May 17, 丨 Haohai Biotechnology (06826.HK) issued an announcement. On May 17, 2024, it spent RMB 4.3037 million to repurchase 47,200 A shares at a repurchase price of 90.32-91.76 yuan per share.
Hong Kong Stock Concept Tracking | Beauty Localization Trends Clear, Institutions Optimistic About Industry Sector Allocation Opportunities (with concept stocks)
JD will continue to increase subsidies of 10 billion dollars this year. By the end of April, it will launch an additional bonus function on the consumer settlement page, testing the waters in the beauty category first. The Zhitong Finance App learned that Unilever (UL.US)'s revenue growth in the first quarter exceeded expectations, driven by CEO Hein Schumacher's transformation plan. CITIC Securities's May 17 research report pointed out that advances in biotechnology are driving the low-cost, high-quality supply of raw materials, compounding the advantages of local brands in consumer insight, content marketing, and traffic management. The trend of localization of beauty is clear, and the share of local brands is expected to continue to rise. CITIC Securities recommendations
Haohai Biotechnology (06826) spent 3.371,900 yuan to buy back 36,700 A-shares on May 16
Haohai Biotechnology (06826) announced that on May 16, 2024, the company spent 337.19...
Haohai Biotechnology (06826.HK) spent 1.577 million yuan to buy back 17,000 A shares on May 15
Gelonghui, May 16, 丨 Haohai Biotechnology (06826.HK) issued an announcement. On May 15, 2024, it spent 1.57,700 yuan to repurchase 17,000 A shares at a repurchase price of 91.56-92.73 yuan per share.
Haohai Biotechnology (06826) repurchased 8,200 A shares on May 14
Haohai Biotechnology (06826) issued an announcement to return 758,000 yuan on May 14, 2024...
On May 13, Haohai Biotechnology (06826) spent about 12.372 million yuan to buy back about 133,400 A shares
According to the Zhitong Finance App, Haohai Biotechnology (06826) announced that on May 13, 2024, it spent about 12.372 million yuan to buy back about 133,400 A-shares.
Haohai Biotechnology (06826.HK) did not implement share repurchases in April
Gelonghui, May 6, 丨 Haohai Biotechnology (06826.HK) announced that in April 2024, the company did not implement a share repurchase. As of April 30, 2024, the company has repurchased a total of 1,346,828 A-shares through centralized bidding transactions, accounting for 0.80% of the company's total share capital of 168,707,203 shares. The highest transaction price was 113.50 yuan/share, the minimum transaction price was 84.26 yuan/share, and the total transaction amount was RMB 140,085,716.25 (excluding transaction fees such as stamp duty and transaction commissions).
[Broker Focus] Northeast Securities maintains Haohai Biotechnology's (06826) “buy” rating, indicating that its medical and aesthetic hyaluronic acid is widely recognized by the market
Jinwu Financial News | According to Northeast Securities Research, Haohai Biotechnology (06826) released its 2024 quarterly report. Q1 achieved revenue of 646 million yuan (RMB, same below)/+5.68%, net profit of 98 million yuan/ +20.16%, net profit after deducting non-return to mother 95 million yuan/ +33.05%, and non-recurring profit and loss of 0.2 billion yuan mainly from government subsidies. According to the bank, the company's medical and aesthetic hyaluronic acid performance continues to be outstanding and is expected to be the main source of growth in performance throughout the year. The first generation Helvetia maintained strong growth resilience, and the second generation Guerlain further opened up the market gap through approval of lip indications
昊海生物科技：2024年第一季度報告
Haohai Biotech will pay a final dividend of 1 yuan per share on July 19
Haohai Biotechnology (06826) announced that it will pay a final dividend of RMB 1 per share for the year ended 31 December 2023 on July 19, 2024.
HAOHAI BIOTEC To Go Ex-Dividend On June 6th, 2024 With 1.10175 HKD Dividend Per Share And 0.4 Stock Dividend Per Share
April 27th - $HAOHAI BIOTEC(06826.HK)$ is trading ex-dividend on June 6th, 2024. Shareholders of record on June 7th, 2024 will receive 1.10175 HKD dividend per share and 0.4 stock dividend per sha
Haohai Biotechnology (06826) will pay a final dividend of 1 yuan per share on July 19
Haohai Biotechnology (06826) issued an announcement that it will be distributed on July 19, 2024 until 2024 until 2023...
Haohai Biotechnology (06826.HK) plans to hold a board meeting on April 29 to approve the first quarter results
Gelonghui, April 17, 丨 Haohai Biotechnology (06826.HK) issued an announcement. The board of directors hereby announces that a board meeting will be held on April 29, 2024 (Monday) to review and approve (including) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
昊海生物科技：董事會會議召開日期
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
HAOHAI BIOTEC: ANNUAL REPORT 2023
Haohai Biotechnology (06826) did not implement share repurchases in March and has repurchased a total of about 1.346,800 A-shares
According to the Zhitong Finance App, Haohai Biotechnology (06826) announced the progress of repurchasing the company's A shares through centralized bidding transactions. In March 2024, the company did not implement a share repurchase. As of March 31, 2024, the company has repurchased approximately 1,346,800 A-shares of the company through centralized bidding transactions, accounting for 0.80% of the company's total share capital. The highest transaction price was 113.50 yuan/share, the lowest transaction price was 84.26 yuan/share, and the total transaction amount was approximately RMB 140 million (excluding transaction fees such as stamp duty and transaction commissions).
Shen Wan Hongyuan: The beauty market has entered a stage of steady development and is optimistic about the market space and performance transformation of key domestic brands
China's beauty market has left a decade of rapid growth and has entered a stage of steady development.
Haohai Biotechnology (06826): 526,400 A-share restricted shares will be listed and circulated on April 1
Haohai Biotechnology (06826) issued an announcement regarding the first grant of the 2021 A-share Restricted Stock Incentive Plan to the Ministry...
Haohai Biotech's hyaluronic acid is still a good business, but ophthalmology is more complicated
“Investor Network” Cai Jun's hyaluronic acid competition among the Three Musketeers of Medicine and Aesthetics is getting hotter and hotter. Recently, Haohai Biotech (688366.SH, hereinafter referred to as the “Company”) and Aimeike released their 2023 Annual Report. During the reporting period, the company's operating income and net profit attributable to shareholders of listed companies were 2,654 million yuan and 416 million yuan respectively, up 24.59% and 130.58% year-on-year respectively. In the same period, Aimeike's operating revenue and net profit attributable to shareholders of listed companies were 2.87 billion yuan and 1,858 billion yuan respectively, up 47.99% and 47.08% year-on-year respectively. It should be pointed out that doctors who love American customers
Analysis
Price Target
No Data
